United States: Q3 2018 Quarterly VC Update: Bruce Booth On The State Of Venture Capital Investing

Last Updated: November 2 2018
Article by Brent D. Fassett

In conjunction with our Q3 Venture Financing Report, I sat down with Bruce Booth from Atlas Venture to get his take on the state of venture capital investing.

A few highlights from Bruce Booth

On deal terms: The pendulum is definitely favoring entrepreneurs and founders, which in life sciences also typically includes venture creation-focused investors.

On shifting dynamics: These trends bring life sciences terms closer to where technology terms have been in recent years – where companies and entrepreneurs have many options to play off each other.

On pharma deal flow: There's been a real disconnect between pharma partnering and the equity capital markets recently, in particular around M&A. ... If the equity markets cool considerably, I would anticipate an increase in pharma dealmaking.

On market outlook: I think we'll see a cooling of venture financing and public offerings through the end of 2018 with a likely resurgence in early 2019 as markets stabilize and IPO activity picks up again.

Based on Cooley data for the year, how does your experience in the market compare? Similar/different? Any surprises?

The Cooley venture financing data is very much in line with what we're seeing in the markets, at least through September 2018. There's a plethora of capital coming to venture, and it's driving up both round sizes and valuations across the board, including early through late-stage startups. Over the past six years, up rounds have become the norm, representing nearly 90% of Q3 2018 financings. In short, abundant capital is chasing a limited number of deals.

As far as VC deal terms, is the pendulum favoring companies or investors, and do you think this will continue through to 2019? Are there any noticeable trends for early stage deals as compared to later-stage deals?

The pendulum is definitely favoring entrepreneurs and founders, which in life sciences also typically includes venture creation-focused investors. Most of the capital is coming into Series B and later rounds – often at attractive step-ups in value from the earlier rounds of financing. The number of rounds raising north of $100 million is more than five times where it was just a few years ago.

In terms of where we go from here, it's hard to know how long the prevailing "risk-off" sentiment in the public equity markets will continue. October 2018 has been one of the worst months in a decade, with biotech indices off about 20% and general equities over 10%. I think we'll see a cooling of venture financing and public offerings through the end of 2018 with a likely resurgence in early 2019 as markets stabilize and IPO activity picks up again.

Any current trends that stand out to you in Q1-Q3 that are changes from 2017? How does the life sciences industry differ from tech in this respect?

I think the long-term trend toward more company-friendly terms is worth noting. Tranching, once in the majority of life sciences deals only a few years ago, is now a distinct minority (one in five financings). Further, using participating preferred securities of some flavor was also very common – in 60% or so of life sciences venture rounds only a few years ago. Today those terms are used in less than one-third of financings. These trends bring life sciences terms closer to where technology terms have been in recent years – where companies and entrepreneurs have many options to play off each other.

Valuations are near historic highs for almost all stages of deals – does Atlas fear overpaying for deals? How challenging is it to put money to work in this environment?

We are early stage investors focused on new venture creation. That is, we predominantly back startups that we help co-found, incubate and seed in our offices around compelling science. Because of this, we generally don't jump into later-stage rounds where the larger valuations have become common. Given the recent rapid trajectories of biotech companies into the public markets or early M&A deals, later-stage investors have to weigh higher valuations with the reality of missing out on compelling biotech IPOs and acquisitions.

As life sciences companies receive investor support, what trends are you seeing in terms of partnering and licensing deals?

There's been a real disconnect between pharma partnering and the equity capital markets recently, in particular around M&A. Private biotech M&A has gone quiet for most of 2017/2018, and the equity markets were willing and able to fund startups at attractive costs of capital to further develop their own assets internally. The traditional power dynamic – where pharma and the public buyside "compete" for private biotech assets – has largely shifted in the past 18 months. If the equity markets cool considerably, I would anticipate an increase in pharma dealmaking.

Are you bullish or bearish on the accessibility of capital markets to life sciences companies as we progress through Q4 and head into 2019?

Given the October effect, I think we're moving into a quarter where there will be some tightening of the financing markets. I've heard several bankers and public buyside fund managers comment that they are "pencils down" for the rest of 2018. I think we'll see things resume with more momentum in the private and public capital markets in Q12019 when some of the macro issues have settled out.

About Bruce Booth

Bruce Booth is a partner at Atlas Venture, where he focuses on novel biopharmaceutical products, therapeutic platforms and innovative biomedical technologies. Bruce is chairman of Kymera Therapeutics, HotSpot Therapeutics, miRagen Therapeutics, Nimbus Therapeutics, Rodin Therapeutics and Unum Therapeutics, and he serves on the boards of Lysosomal Therapeutics and Magenta Therapeutics. Bruce also serves as an advisor in various capacities to UCB, Takeda and the Bill & Melinda Gates Foundation and serves on the board of the National Venture Capital Association.

Bruce blogs about biotech and venture capital topics at LifeSciVC, which is syndicated by Forbes. He has published numerous scientific papers and has authored various biotech venture capital review articles, including several in Nature Biotechnology. Prior to joining Atlas in 2005, he was a consultant at McKinsey & Company and an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a doctorate degree in molecular immunology from Oxford University. He received a bachelor's degree in biochemistry, summa cum laude, from The Pennsylvania State University.

About Atlas Venture

Atlas Venture is a venture capital firm founded in 1980 and headquartered in Cambridge, Massachusetts. The firm seeks to invest in breakthrough biotech companies with remarkable life sciences entrepreneurs. Its portfolio spans a spectrum of investment approaches, from asset-centric product plays to big biology drug discovery platforms.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions